(Q35041311)

6 August 2017

1 reference

title

Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials (English)

1 reference

6 August 2017

1 reference

1 reference

1 reference

2

Andrew Bottomley

1 reference

6 August 2017

1

Fabio Efficace

1 reference

6 August 2017

George van Andel

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

97

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

377-388

1 reference

Irresponsible authorship and wasteful publication

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

Impact of covert duplicate publication on meta-analysis: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

Quality of life as an outcome measure in cancer clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Endpoints in cancer clinical trials: is there a need for measuring quality of life?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Methodologic assessments of quality of life measures in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Quality of life instruments in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Assessment of quality of life in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Reporting on quality of life in randomised controlled trials: bibliographic study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

A review of quality-of-life evaluations in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Assessment of endpoints for clinical trials for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Who should measure quality of life, the doctor or the patient?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Perception of quality of life by patients, partners and treating physicians.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Guidelines for reporting results of quality of life assessments in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Report on the quality of life analysis from the phase III trial of pion versus photon radiotherapy in locally advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Redundancy, disaggregation, and the integrity of medical research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Pion conformal radiation of prostate cancer: results of a randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11065

7 January 2021

Identifiers

DOI

10.1002/CNCR.11065

1 reference

6 August 2017

1 reference